Erratum to: Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex® 10% Versus Gammaplex® 5% in Subjects with Primary Immunodeficiency

Eitemau Tebyg

• Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex(®) 10% Versus Gammaplex(®) 5% in Subjects with Primary Immunodeficiency
  gan: Wasserman, Richard L., et al.
  Cyhoeddwyd: (2017)
• Efficacy and safety of Gammaplex(®) 5% in children and adolescents with primary immunodeficiency diseases
  gan: Melamed, I. R., et al.
  Cyhoeddwyd: (2016)
• Safety, Efficacy and Pharmacokinetics of a New 10% Liquid Intravenous Immunoglobulin (IVIG) in Patients with Primary Immunodeficiency
  gan: Wasserman, Richard L., et al.
  Cyhoeddwyd: (2012)
• Efficacy and safety of a new immunoglobulin G product, Gammaplex®, in primary immunodeficiency diseases
  gan: Moy, J N, et al.
  Cyhoeddwyd: (2010)
• Efficacy, Safety, and Pharmacokinetics of a New 10 % Liquid Intravenous Immunoglobulin Containing High Titer Neutralizing Antibody to RSV and Other Respiratory Viruses in Subjects with Primary Immunodeficiency Disease
  gan: Wasserman, Richard L., et al.
  Cyhoeddwyd: (2016)